Covid-19 affects people differently. NC firm looks to figure out why.
A well known phenomenon of the Covid-19 era is that the deadly virus presents a wide disparity of symptoms between patients – now a Triangle firm has the federal funding to try to find out why.
Last week, Morrisville-based Metabolon was selected by the National Institute of Allergy and Infectious Diseases (NIAID) to be a lead in its "Immunophenotyping Assessment in a Covid-19 Cohort," or IMPACC, study.
The study i s an initiative to dive into the human immune system response to the virus behind…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Seth Thomas Gulledge Source Type: news
More News: Allergy | Allergy & Immunology | COVID-19 | Funding | Health Management | Infectious Diseases | Pharmaceuticals | Study